ICECURE MEDICAL LTD
ICCMNASDAQπ #5092 by market capEarnings Nov 2US Equity
ββ
Quote unavailableTrack ICCM
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$4M
Small Cap
πRevenue Growth (YoY)
41.6%
High Growth
πGross Margin
36.1%
Healthy
π΅FCF Margin
β
βοΈP/S Ratio
0.9x
Cheap
Otter Score
β
Insufficient data
No chart data available for ICCM.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $0.96 β $24.90
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 3.4M
- Next Earnings
- 2026-11-02
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $907,000
- P/E Ratio
- β
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-6.73
- Dividend Yield
- β
- Dilution (1yr)
- +31.0%
ICECURE MEDICAL LTD
ICCMFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3Mβ² +2.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
36.3%βΌ β17.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$15MβΌ β3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$15Mβ² +15.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
2.4Mβ² +31.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9Mβ² +$2M YoY
About ICECURE MEDICAL LTD
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for the women's health and oncology markets. The company is headquartered in Caesarea, Israel.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.